{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-22-000392","form_type":"8-K/A","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.240727+00:00","generated_at":"2026-06-23T14:09:48.830366+00:00","sec_items":["9.01","7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements","bullets":["82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.","NE3107 significantly reduced TNF-alpha; improvements in cognition correlated with TNF reduction (R=0.70, p=0.0077).","Phase 3 AD trial (NCT04669028) half enrolled; topline data expected mid-2023, subject to DSMB review.","Phase 2 Parkinson's trial (NCT05083260) enrolling; data readout by end of 2022; early efficacy signal detected.","Phase 2b BIV201 trial for ascites delayed by COVID; data readout anticipated mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-22-000392","json":"https://secwatch.observer/filing/0001520138-22-000392.json","markdown":"https://secwatch.observer/filing/0001520138-22-000392.md","text":"https://secwatch.observer/filing/0001520138-22-000392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/0001520138-22-000392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/bivi-20220907_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:09:48.830366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}